Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.

Authors:
Alita Kongchanagul Karnyart Samnuan Ponthip Wirachwong Somchaiya Surichan Pilaipan Puthavathana Punnee Pitisuttithum Kobporn Boonnak

Vaccine 2020 01 7;38(4):852-858. Epub 2019 Nov 7.

Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Thailand. Electronic address:

Background: The emergence and spread of highly pathogenic avian influenza (H5N1) viruses have raised global concerns of a possible human pandemic, spurring efforts towards H5N1 influenza vaccine development and improvements in vaccine administration methods. We previously showed that a prime-boost vaccination strategy induces robust and broadly cross-reactive antibody responses against the hemagglutinin globular head domain. Here, we specifically measure antibodies against the conserved hemagglutinin stem region in serum samples obtained from the prior study to determine whether stalk-reactive antibodies can also be induced by the prime-boost regimen.

Method: Serum samples collected from 60 participants before vaccination and on days 7, 28 and 90 following boosting vaccination were used in this study. 40 participants received two doses of live attenuated H5N2 vaccine (LAIV H5N2) followed by one dose of inactivated H5N1 vaccine a year later, while 20 participants received only the inactivated H5N1 vaccine. We tested these serum samples for stalk-reactive antibodies via enzyme-linked immunosorbent (ELISA) and microneutralization assays.

Results: Stalk-specific antibody levels measured by both assays were found to be significantly higher in primed individuals than the unprimed group. ELISA results showed that 22.5, 70.5 and 57.5% of primed participants had a four-fold or more increase in stalk antibody titers on days 7, 28 and 90 following boosting vaccination, respectively; whereas the unprimed group had no increase. Peak geometric mean titers (GMT) for stalk antibodies in the LAIV H5N2 experienced group (24,675 [95% CI; 19,531-31,174]) were significantly higher than those who received only the inactivated H5N1 vaccine (8877 [7140-11,035]; p < 0·0001). Moreover, stalk antibodies displaying neutralizing activity also increased in primed participants, but not in the unprimed group.

Conclusion: Our finding emphasizes the importance of prime-boost vaccination for effectively inducing stalk antibodies, which is an attractive target for developing vaccines that induce stalk reactive antibodies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2019.10.084DOI Listing
January 2020

Publication Analysis

Top Keywords

inactivated h5n1
16
h5n1 vaccine
12
serum samples
12
days boosting
8
boosting vaccination
8
laiv h5n2
8
unprimed group
8
received inactivated
8
antibody responses
8
participants received
8
stalk-reactive antibodies
8
attenuated h5n2
8
live attenuated
8
vaccine
6
h5n1
6
vaccination
5
dose inactivated
4
h5n2 prime-
4
received doses
4
h5n2 dose
4

Keyword Occurance

Similar Publications

A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1.

Authors:
Jacob Schön Wei Ran Marco Gorka Martin Schwemmle Martin Beer Donata Hoffmann

NPJ Vaccines 2020 May 15;5(1):40. Epub 2020 May 15.

Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany.

Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. Read More

View Article and Full-Text PDF
May 2020
Similar Publications

A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

Authors:
Kenta Matsuda Stephen A Migueles Jinghe Huang Lyuba Bolkhovitinov Sarah Stuccio Trevor Griesman Alyssa A Pullano Byong H Kang Elise Ishida Matthew Zimmerman Neena Kashyap Kelly M Martins Daniel Stadlbauer Jessica Pederson Andy Patamawenu Nathaniel Wright Tulley Shofner Sean Evans C Jason Liang Julián Candia Angelique Biancotto Giovanna Fantoni April Poole Jon Smith Jeff Alexander Marc Gurwith Florian Krammer Mark Connors

J Clin Invest 2021 03;131(5)

HIV-Specific Immunity Section of the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.

BACKGROUNDTo understand the features of a replicating vaccine that might drive potent and durable immune responses to transgene-encoded antigens, we tested a replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray.METHODSViral shedding from the nose, mouth, and rectum was measured by PCR and culturing. H5-specific IgG and IgA antibodies were measured by bead array binding assays. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

A broad spectrum HVT-H5 avian influenza vector vaccine which induces a rapid onset of immunity.

Authors:
Sylvia Reemers Iwan Verstegen Stephanie Basten Willem Hubers Saskia van de Zande

Vaccine 2021 Feb 19;39(7):1072-1079. Epub 2021 Jan 19.

MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, the Netherlands.

Current methods to combat highly pathogenic avian influenza (HPAI) outbreaks in poultry rely on stamping out and preventive culling, which can lead to high economic losses and invoke ethical resistance. Emergency vaccination could be an alternative as vaccination is one of the most efficient and cost-effective measures to protect poultry from HPAI infection, preventing spreading to other poultry and greatly reducing the potential transmission to humans. Current conventional inactivated AI vaccines may be useful for combating AI outbreaks, but do not fulfil all targets of an ideal AI vaccine, including mass applicability and rapid onset of immunity. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

A single dose of inactivated oil-emulsion bivalent H5N8/H5N1 vaccine protects chickens against the lethal challenge of both highly pathogenic avian influenza viruses.

Authors:
Mahmoud Ibrahim Salah Zakaria Abdel-Hamid I Bazid Walid H Kilany Mohamed A Zain El-Abideen Ahmed Ali

Comp Immunol Microbiol Infect Dis 2021 Feb 25;74:101601. Epub 2020 Nov 25.

Poultry Diseases Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, 62511, Egypt. Electronic address:

In this study, two highly pathogenic avian influenza (HPAI) H5N8 viruses were isolated from chicken and geese in 2018 and 2019 (Chicken/ME-2018 and Geese/Egypt/MG4/2019). The hemagglutinin and neuraminidase gene analyses revealed their close relatedness to the clade-2.3. Read More

View Article and Full-Text PDF
February 2021
Similar Publications

A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.

Authors:
Xingui Tian Shelby Landreth Yao Lu Kannupriya Pandey Yan Zhou

J Virol 2021 01 13;95(3). Epub 2021 Jan 13.

Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, Saskatchewan, Canada

The recent highly pathogenic avian influenza (HPAI) H5N1 and H7N9 viruses have caused hundreds of human infections with high mortality rates. Although H5N1 and H7N9 viruses have been limited mainly to avian species, there is high potential for these viruses to acquire human-to-human transmission and initiate a pandemic. A highly safe and effective vaccine is needed to protect against a potential H5N1 or H7N9 influenza pandemic. Read More

View Article and Full-Text PDF
January 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap